Novavax (NVAX) Common Equity (2010 - 2026)
Novavax (NVAX) posted quarterly Common Equity of -$144.8 million for Q1 2026, down 91.38% year-over-year from -$1.7 billion in Q1 2025, and down 13.31% quarter-over-quarter from -$127.8 million in Q4 2025.
Novavax (NVAX) Common Equity (2010 - 2026) Analysis & Trends
Novavax's Common Equity history runs 17 years deep, the most recent figure standing at -$144.8 million for Q1 2026.
- In Q1 2026, Common Equity fell 91.38% year-over-year to -$144.8 million; the TTM figure through Mar 2026 stood at -$144.8 million (down 91.38% YoY), while the FY2025 annual figure was -$127.8 million, up 79.52% from the prior year.
- Common Equity for Q1 2026 stood at -$144.8 million, down from -$127.8 million in the prior quarter.
- The five-year high for Common Equity was $65.3 million in Q1 2022, with the low at -$895.6 million in Q1 2023.
- The 5-year median for Common Equity is -$526.4 million (2024), against an average of -$442.0 million.
- The sharpest annual moves came in 2023 and 2025: Common Equity sank 1470.98% in 2023, then jumped 108.72% in 2025.
- Novavax's Common Equity stood at -$634.1 million in 2022, then dropped by 13.07% to -$716.9 million in 2023, then grew by 12.98% to -$623.8 million in 2024, then surged by 79.52% to -$127.8 million in 2025, then retreated by 13.31% to -$144.8 million in 2026.
- Business Quant data shows NVAX's Common Equity at -$144.8 million in Q1 2026, -$127.8 million in Q4 2025, and -$156.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -190.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -190.71 Mn |
| Mar 31, 2026 | -144.76 Mn |
| Dec 31, 2025 | -127.75 Mn |
| Sep 30, 2025 | -156.67 Mn |
| Jun 30, 2025 | 37.63 Mn |
| Mar 31, 2025 | -75.64 Mn |
| Dec 31, 2024 | -623.84 Mn |
| Sep 30, 2024 | -526.44 Mn |
| Jun 30, 2024 | -431.71 Mn |
| Mar 31, 2024 | -867.08 Mn |
| Dec 31, 2023 | -716.93 Mn |
| Sep 30, 2023 | -678.35 Mn |
| Jun 30, 2023 | -754.52 Mn |
| Mar 31, 2023 | -895.58 Mn |
| Dec 31, 2022 | -634.08 Mn |
| Sep 30, 2022 | -565.99 Mn |
| Jun 30, 2022 | -416.95 Mn |
| Mar 31, 2022 | 65.32 Mn |
| Dec 31, 2021 | -351.67 Mn |
| Sep 30, 2021 | 461.34 Mn |